APOE ε4 and bapineuzumab Infusing pharmacogenomics into Alzheimer disease therapeutics

被引：23

作者：

Kaufer, Dan ^{[1
]}

Gandy, Sam ^{[2
,3
]}

机构：

[1] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA

[2] Mt Sinai Sch Med, Dept Neurol & Psychiat, New York, NY USA

[3] James J Peters Vet Affairs Med Ctr, Bronx, NY USA

来源：

NEUROLOGY | 2009年 / 73卷 / 24期

关键词：

APOLIPOPROTEIN E4; IMMUNIZATION; PATHOLOGY;

D O I：

10.1212/WNL.0b013e3181c6784a

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

引用

页码：2052 / 2053

页数：2

共 10 条

[1]

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization [J].

Orgogozo, JM ;

Gilman, S ;

Dartigues, JF ;

Laurent, B ;

Puel, M ;

Kirby, LC ;

Jouanny, P ;

Dubois, B ;

Eisner, L ;

Flitman, S ;

Michel, BF ;

Boada, M ;

Frank, A ;

Hock, C .

NEUROLOGY, 2003, 61 (01) :46-54

[2]

Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice [J].

Petrushina, Irina ;

Ghochikyan, Anahit ;

Mktrichyan, Mikayel ;

Mamikonyan, Gregory ;

Movsesyan, Nina ;

Davtyan, Hayk ;

Patel, Archita ;

Head, Elizabeth ;

Cribbs, David H. ;

Agadjanyan, Michael G. .

JOURNAL OF NEUROSCIENCE, 2007, 27 (46) :12721-12731

[3]

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease [J].

Poirier, J ;

Delisle, MC ;

Quirion, R ;

Aubert, I ;

Farlow, M ;

Lahiri, D ;

Hui, S ;

Bertrand, P ;

Nalbantoglu, J ;

Gilfix, BM ;

Gauthier, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (26) :12260-12264

[4]

Premkumar DRD, 1996, AM J PATHOL, V148, P2083

[5]

Effects of β-hydroxybutyrate on cognition in memory-impaired adults [J].

Reger, MA ;

Henderson, ST ;

Hale, C ;

Cholerton, B ;

Baker, LD ;

Watson, GS ;

Hyde, K ;

Chapman, D ;

Craft, S .

NEUROBIOLOGY OF AGING, 2004, 25 (03) :311-314

[6]

Relkin NR, 2007, ALZHEIMERS DEMENT, V3, pS196, DOI 10.1016/j.jalz.2007.04.021

[7]

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease [J].

Risner, M. E. ;

Saunders, A. M. ;

Altman, J. F. B. ;

Ormandy, G. C. ;

Craft, S. ;

Foley, I. M. ;

Zvartau-Hind, M. E. ;

Hosford, D. A. ;

Roses, A. D. .

PHARMACOGENOMICS JOURNAL, 2006, 6 (04) :246-254

[8]

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease [J].

Salloway, S. ;

Sperling, R. ;

Gilman, S. ;

Fox, N. C. ;

Blennow, K. ;

Raskind, M. ;

Sabbagh, M. ;

Honig, L. S. ;

Doody, R. ;

van Dyck, C. H. ;

Mulnard, R. ;

Barakos, J. ;

Gregg, K. M. ;

Liu, E. ;

Lieberburg, I. ;

Schenk, D. ;

Black, R. ;

Grundman, M. .

NEUROLOGY, 2009, 73 (24) :2061-2070

[9]

Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse [J].

Schenk, D ;

Barbour, R ;

Dunn, W ;

Gordon, G ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Liao, ZM ;

Lieberburg, I ;

Motter, R ;

Mutter, L ;

Soriano, F ;

Shopp, G ;

Vasquez, N ;

Vandevert, C ;

Walker, S ;

Wogulis, M ;

Yednock, T ;

Games, D ;

Seubert, P .

NATURE, 1999, 400 (6740) :173-177

[10]

Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure [J].

Zhong, Ning ;

Weisgraber, Karl H. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (10) :6027-6031

← 1 →